Hypoxia-dependent drivers of melanoma progression

1.

Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer. 1998;83:1664–78 Available from: https://pubmed.ncbi.nlm.nih.gov/9781962/. Cited 2020 Aug 22.PubMedCrossRef

2.

Mikkelsen LH, Larsen AC, von Buchwald C, Drzewiecki KT, Prause JU, Heegaard S. Mucosal malignant melanoma – a clinical, oncological, pathological and genetic survey. APMIS. 2016;124:475–86 Blackwell Munksgaard. Available from: https://pubmed.ncbi.nlm.nih.gov/27004972/. Cited 2020 Dec 14.PubMedCrossRef

3.

Rodrigues M, de Koning L, Coupland SE, Jochemsen AG, Marais R, Stern MH, et al. So close, yet so far: discrepancies between uveal and other melanomas. a position paper from UM cure 2020. Cancers (Basel). 2019;11:1032 MDPI AG. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678543/. Cited 2020 Sep 11.

4.

Brustugun OT. Hypoxia as a cause of treatment failure in non-small cell carcinoma of the lung. Semin Radiat Oncol. 2015:87–92 W.B. Saunders. Available from: https://pubmed.ncbi.nlm.nih.gov/25771412/. Cited 2020 Dec 9.

5.

Manoochehri Khoshinani H, Afshar S, Najafi R. Hypoxia: a double-edged sword in cancer therapy. Cancer Investig. 2016:536–45 Taylor and Francis Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/27824512/. Cited 2020 Dec 15.

6.

Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology. 2014;143:512–9 Blackwell Publishing Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/25196648/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

7.

Van Den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun. 2014;5 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/25351418/. Cited 2020 Dec 9.

8.

Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019; BioMed Central Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/31711497/. Cited 2020 Dec 15.

9.

You L, Wu W, Wang X, Fang L, Adam V, Nepovimova E, et al. The role of hypoxia-inducible factor 1 in tumor immune evasion. Med Res Rev. 2020. John Wiley and Sons Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/33305856/. Cited 2020 Dec 30

10.

Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis. 2003:237–50 Available from: https://pubmed.ncbi.nlm.nih.gov/12741682/. Cited 2020 Dec 9.

11.

Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004:437–47 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/15170446/. Cited 2020 Dec 9.

12.

Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010:294–309 Available from: https://pubmed.ncbi.nlm.nih.gov/20965423/. Cited 2020 Dec 9.

13.

Abramovitch R, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, Pappo O, et al. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res. 2004;64:1338–46 Available from: https://pubmed.ncbi.nlm.nih.gov/14973073/. Cited 2020 Dec 9.PubMedCrossRef

14.

Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 2003:1021–8 Available from: https://pubmed.ncbi.nlm.nih.gov/14662015/. Cited 2020 Dec 9.

15.

Acker T, Plate KH. Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. Cancer Treat Res. 2004:219–48 Available from: https://pubmed.ncbi.nlm.nih.gov/15015563/. Cited 2020 Dec 18.

16.

Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999:551–78 Available from: https://pubmed.ncbi.nlm.nih.gov/10611972/. Cited 2020 Dec 9.

17.

Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016:175–80 American Association for the Advancement of Science. Available from: https://pubmed.ncbi.nlm.nih.gov/27124451/. Cited 2020 Dec 9.

18.

Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factors--similar but not identical. Mol Cell. 2010;29(5):435-42.

19.

Heikkilä M, Pasanen A, Kivirikko KI, Myllyharju J. Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response. Cell Mol Life Sci. 2011;68:3885–901 Available from: https://pubmed.ncbi.nlm.nih.gov/21479871/. Cited 2021 Mar 3.PubMedCrossRef

20.

Pezzuto A, Carico E. Role of HIF-1 in cancer progression: novel insights. A Review. Curr Mol Med. 2018;18:343–51 Bentham Science Publishers Ltd.. Available from: https://pubmed.ncbi.nlm.nih.gov/30411685/. Cited 2021 Mar 3.PubMedCrossRef

21.

Hayashi Y, Yokota A, Harada H, Huang G. Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1α in cancer. Cancer Sci. 2019:1510–7 Blackwell Publishing Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/30844107/. Cited 2021 Mar 3.

22.

Paredes F, Williams HC, San Martin A. Metabolic adaptation in hypoxia and cancer. Cancer Lett. 2021:133–42 Elsevier Ireland Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/33444690/. Cited 2021 Mar 3.

23.

Peng X, Gao H, Xu R, Wang H, Mei J, Liu C. Correction to: the interplay between HIF-1α and noncoding RNAs in cancer. J Exp Clin Cancer Res. 2020;39:45 Available from: http://creativecommons.org/publicdomain/zero/1.0/. Cited 2021 Mar 3.PubMedPubMedCentralCrossRef

24.

Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, et al. Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol. 2018:1071–80 Spandidos Publications. Available from: https://pubmed.ncbi.nlm.nih.gov/29532857/. Cited 2020 Dec 15.

25.

Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatol. 2020; Elsevier B.V. Available from: https://pubmed.ncbi.nlm.nih.gov/32268150/. Cited 2020 Dec 15.

26.

WH W, JM F. Cutaneous melanoma: etiology and therapy. Cutan Melanoma Etiol Ther. 2017; Codon Publications. Available from: https://pubmed.ncbi.nlm.nih.gov/29461771/. Cited 2021 Mar 3.

27.

Olsen CM, Thompson JF, Pandeya N, Whiteman DC. Evaluation of sex-specific incidence of melanoma. JAMA Dermatology. 2020;156:553–60 American Medical Association.PubMedCrossRef

28.

Pennello G, Devesa S, Gail M. Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks. AACR. 2000;9(3):291-7. Available from: https://cebp.aacrjournals.org/content/9/3/291.short.

29.

Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45–60 Available from: https://pubmed.ncbi.nlm.nih.gov/15617990/. Cited 2020 Dec 15.PubMedCrossRef

30.

Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res. 2003:297–306 Available from: https://pubmed.ncbi.nlm.nih.gov/12753404/. Cited 2020 Dec 15.

31.

Hawkes JE, Truong A, Meyer LJ. Genetic predisposition to melanoma. Semin Oncol. 2016:591–7 W.B. Saunders. Available from: https://pubmed.ncbi.nlm.nih.gov/27899192/. Cited 2020 Dec 15.

32.

Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 2017:2104–17 Wiley. Available from: https://pubmed.ncbi.nlm.nih.gov/28543693/. Cited 2020 Dec 15.

33.

Mikkelsen LH, Maag E, Andersen MK, Kruhøffer M, Larsen AC, Melchior LC, et al. The molecular profile of mucosal melanoma. Melanoma Res. 2020;30:533–42 NLM (Medline). Available from: https://pubmed.ncbi.nlm.nih.gov/33156594/. Cited 2020 Dec 14.PubMedCrossRef

34.

Monsel G, Ortonne N, Bagot M, Bensussan A, Dumaz N. C-Kit mutants require hypoxia-inducible factor 1α to transform melanocytes. Oncogene. 2010;29:227–36 Available from: https://pubmed.ncbi.nlm.nih.gov/19802003/. Cited 2020 Dec 14.PubMedCrossRef

35.

Raica M, Jitariu AA, Cimpean AM. Lymphangiogenesis and anti-lymphangiogenesis in cutaneous melanoma. Anticancer Res. 2016:4427–35 International Institute of Anticancer Research. Available from: https://pubmed.ncbi.nlm.nih.gov/27630278/. Cited 2020 Dec 14.

36.

Bedogni B, Powell MB. Unique transforming properties of Notch1 in human melanocytes. Pigment Cell Melanoma Res. 2009:702–3 Available from: https://pubmed.ncbi.nlm.nih.gov/19708913/. Cited 2020 Dec 15.

37.

Lartigau E, Randrianarivelo H, Avril MF, Margulis A, Spatz A, Eschwège F, et al. Intratumoral oxygen tension in metastatic melanoma. Melanoma Res. 1997;7:400–6 Lippincott Williams and Wilkins. Available from: https://pubmed.ncbi.nlm.nih.gov/9429223/. Cited 2020 Dec 15.PubMedCrossRef

38.

Boutin AT, Weidemann A, Fu Z, Mesropian L, Gradin K, Jamora C, et al. Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell. 2008;133:223–34 Available from: https://pubmed.ncbi.nlm.nih.gov/18423195/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

39.

Bedogni B, Powell MB. Skin hypoxia: a promoting environmental factor in melanomagenesis. Cell Cycle. 2006:1258–61 Taylor and Francis Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/16760649/. Cited 2020 Dec 15.

40.

Haq R, Fisher DE. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol. 2011:3474–82 Available from: https://pubmed.ncbi.nlm.nih.gov/21670463/. Cited 2020 Dec 15.

41.

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436:117–22 Available from: https://pubmed.ncbi.nlm.nih.gov/16001072/. Cited 2020 Dec 15.PubMedCrossRef

42.

Bertolotto C, Lesueur F, Giuliano S, Strub T, De Lichy M, Bille K, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011;480:94–8 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/22012259/. Cited 2020 Dec 15.PubMedCrossRef

43.

Buscà R, Berra E, Gaggioli C, Khaled M, Bille K, Marchetti B, et al. Hypoxia-inducible factor 1α is a new target of microphthalmia- associated transcription factor (MITF) in melanoma cells. J Cell Biol. 2005;170:49–59 Available from: https://pubmed.ncbi.nlm.nih.gov/15983061/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

44.

Feige E, Yokoyama S, Levy C, Khaled M, Igras V, Lin RJ, et al. Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci U S A. 2011;108 Available from: https://pubmed.ncbi.nlm.nih.gov/21949374/. Cited 2020 Dec 15.

45.

Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, et al. Mutant V600E BRAF increases hypoxia inducible factor-1α expression in melanoma. Cancer Res. 2007;67:3177–84 Available from: https://pubmed.ncbi.nlm.nih.gov/17409425/. Cited 2020 Dec 15.PubMedCrossRef

46.

Nys K, Maes H, Dudek AM, Agostinis P. Uncovering the role of hypoxia inducible factor-1α in skin carcinogenesis. Biochim Biophys Acta - Rev Cancer. 2011:1–12 Available from: https://pubmed.ncbi.nlm.nih.gov/21338656/. Cited 2020 Dec 15.

47.

Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest. 2008;118:3660–70 Available from: https://pubmed.ncbi.nlm.nih.gov/18924608/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

48.

Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, del Bufalo D. Bcl-2 regulates HIF-1α protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One. 2010;5 Available from: https://pubmed.ncbi.nlm.nih.gov/20668552/. Cited 2020 Dec 16.

49.

Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK. Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer. 2010;46:1159–69 Available from: https://pubmed.ncbi.nlm.nih.gov/20185296/. Cited 2020 Dec 15.PubMedCrossRef

50.

Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M, et al. Prognostic relevance of hypoxia inducible factor-1α expression in patients with melanoma. Clin Exp Dermatol. 2009;34 Available from: https://pubmed.ncbi.nlm.nih.gov/20055873/. Cited 2020 Dec 15.

51.

Mills CN, Joshi SS, Niles RM. Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol Cancer. 2009;8 Available from: https://pubmed.ncbi.nlm.nih.gov/19919690/. Cited 2020 Dec 15.

52.

Zbytek B, Peacock DL, Seagroves TN, Slominski A. Putative role of hif transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol. 2013:239–51 Available from: https://pubmed.ncbi.nlm.nih.gov/24194964/. Cited 2020 Dec 15.

53.

Marconi A, Borroni RG, Truzzi F, Longo C, Pistoni F, Pellacani G, et al. Hypoxia-inducible factor-1α and CD271 inversely correlate with melanoma invasiveness. Exp Dermatol. 2015:396–8 Blackwell Publishing Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/25739328/. Cited 2020 Dec 15.

54.

Martínez-García MÁ, Riveiro-Falkenbach E, Rodríguez-Peralto JL, Nagore E, Martorell-Calatayud A, Campos-Rodríguez F, et al. A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1α and VEGF expressions. Melanoma Res. 2017;27:558–64 Lippincott Williams and Wilkins. Available from: https://pubmed.ncbi.nlm.nih.gov/28885396/. Cited 2020 Dec 15.PubMedCrossRef

55.

Quaresmini D, Guida M. Neoangiogenesis in melanoma: an issue in biology and systemic treatment. Front Immunol. 2020; Frontiers Media S.A. Available from: https://pubmed.ncbi.nlm.nih.gov/33193402/. Cited 2021 Mar 3.

56.

Cho WC, Jour G, Aung PP. Role of angiogenesis in melanoma progression: update on key angiogenic mechanisms and other associated components. Semin Cancer Biol. 2019:175–86 Academic Press. Available from: https://pubmed.ncbi.nlm.nih.gov/31255774/. Cited 2021 Mar 3.

57.

Jour G, Ivan D, Aung PP. Angiogenesis in melanoma: an update with a focus on current targeted therapies. J Clin Pathol. 2016:472–83 BMJ Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/26865640/. Cited 2021 Mar 3.

58.

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22 Wiley.PubMedCrossRef

59.

Yu JL, Rak JW, Klement G, Kerbel RS. Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res. 2002;62:1838–46 Available from: https://pubmed.ncbi.nlm.nih.gov/11912163/. Cited 2020 Dec 15.PubMed

60.

Ruffini F, Failla CM, Orecchia A, Bani MR, Dorio AS, Fortes C, et al. Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. Br J Dermatol. 2011;164:1061–70 Available from: https://pubmed.ncbi.nlm.nih.gov/21198538/. Cited 2020 Dec 15.PubMedCrossRef

61.

Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009:154–65 Available from: https://pubmed.ncbi.nlm.nih.gov/19230644/. Cited 2020 Dec 15.

62.

Treskova I, Topolcan O, Windrichova J, Simanek V, Slouka D, Treska V, et al. OPG, OPN, EGF and VEGF levels at individual breslow score stages in malignant melanoma. Anticancer Res. 2018;38:4907–11 International Institute of Anticancer Research. Available from: https://pubmed.ncbi.nlm.nih.gov/30061268/. Cited 2020 Dec 15.PubMedCrossRef

63.

Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, et al. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J. 2002;16:1453–5 Available from: https://pubmed.ncbi.nlm.nih.gov/12205045/. Cited 2020 Dec 15.PubMedCrossRef

64.

Trisciuoglio D, Gabellini C, Desideri M, Ragazzoni Y, De Luca T, Ziparo E, et al. Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. Cell Death Differ. 2011;18:1024–35 Available from: https://pubmed.ncbi.nlm.nih.gov/21233846/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

65.

Trisciuoglio D, Tupone MG, Desideri M, Di Martile M, Gabellini C, Buglioni S, et al. BCL-XL overexpression promotes tumor progression-associated properties article. Cell Death Dis. 2017;8 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/29238043/. Cited 2020 Dec 15.

66.

Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe’er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155:739–52 American Society for Investigative Pathology Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/10487832/. Cited 2020 Dec 9.PubMedPubMedCentralCrossRef

67.

Hendrix MJC, Seftor EA, Hess AR, Seftor REB. Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat Rev Cancer. 2003:411–21 Available from: https://pubmed.ncbi.nlm.nih.gov/12778131/. Cited 2020 Dec 9.

68.

Zhang S, Guo H, Zhang D, Zhang W, Zhao X, Ren Z, et al. Microcirculation patterns in different stages of melanoma growth. Oncol Rep. 2006;15:15–20 Spandidos Publications. Available from: https://pubmed.ncbi.nlm.nih.gov/16328029/. Cited 2020 Dec 14.PubMed

69.

Cao Z, Bao M, Miele L, Sarkar FH, Wang Z, Zhou Q. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer. 2013;49:3914–23 Available from: https://pubmed.ncbi.nlm.nih.gov/23992642/. Cited 2020 Dec 15.PubMedCrossRef

70.

Yura Y, Chong BSH, Johnson RD, Watanabe Y, Tsukahara Y, Ferran B, et al. Endothelial cell-specific redox gene modulation inhibits angiogenesis but promotes B16F0 tumor growth in mice. FASEB J. 2019;33:14147–58 NLM (Medline). Available from: https://pubmed.ncbi.nlm.nih.gov/31647879/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

71.

Zhang S, Li M, Zhang D, Xu S, Wang X, Liu Z, et al. Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma. Lab Investig. 2009;89:575–86 Available from: https://pubmed.ncbi.nlm.nih.gov/19290005/. Cited 2020 Dec 15.PubMedCrossRef

72.

Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett. 2007;249:188–97 Available from: https://pubmed.ncbi.nlm.nih.gov/16997457/. Cited 2020 Dec 15.PubMedCrossRef

73.

Spinella F, Caprara V, Cianfrocca R, Rosanò L, Di Castro V, Garrafa E, et al. The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis. 2014;35:840–8 Oxford University Press. Available from: https://pubmed.ncbi.nlm.nih.gov/24473118/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

74.

Comito G, Calvani M, Giannoni E, Bianchini F, Calorini L, Torre E, et al. HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med. 2011;51:893–904 Available from: https://pubmed.ncbi.nlm.nih.gov/21703345/. Cited 2020 Dec 15.PubMedCrossRef

75.

Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1α promotes metastasis. Nat Cell Biol. 2008;10:295–305 Available from: https://pubmed.ncbi.nlm.nih.gov/18297062/. Cited 2020 Dec 15.CrossRefPubMed

76.

Patra K, Jana S, Sarkar A, Mandal DP, Bhattacharjee S. The inhibition of hypoxia-induced angiogenesis and metastasis by cinnamaldehyde is mediated by decreasing HIF-1α protein synthesis via PI3K/Akt pathway. BioFactors. 2019;45:401–15 Blackwell Publishing Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/30854715/. Cited 2020 Dec 15.PubMedCrossRef

77.

Wicklein D, Otto B, Suling A, Elies E, Lüers G, Lange T, et al. CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells. Sci Rep. 2018;8 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/30089785/. Cited 2020 Dec 15.

78.

Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MIG, et al. Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. J Invest Dermatol. 2013;133:2436–43 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/23474946/. Cited 2020 Dec 15.PubMedCrossRef

79.

Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1 1. Cancer Res. 2003; Available from: https://cancerres.aacrjournals.org/content/63/5/1138.short.

80.

Liu W, Shen SM, Zhao XY, Chen GQ. Targeted genes and interacting proteins of hypoxia inducible factor-1. Int J Biochem Mol Biol. 2012:165–78 e-Century Publishing Corporation. Available from: www.ijbmb.org. Cited 2020 Dec 15.

81.

Naldini A, Filippi I, Ardinghi C, Silini A, Giavazzi R, Carraro F. Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. Eur J Cancer. 2009;45:454–60 Available from: https://pubmed.ncbi.nlm.nih.gov/19046876/. Cited 2021 Mar 3.PubMedCrossRef

82.

Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, et al. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 2010:1051–67 Available from: https://pubmed.ncbi.nlm.nih.gov/21080821/. Cited 2020 Dec 15.

83.

Hugdahl E, Bachmann IM, Schuster C, Ladstein RG, Akslen LA. Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma. PLoS One. 2019;14 Public Library of Science. Available from: https://pubmed.ncbi.nlm.nih.gov/30640942/. Cited 2020 Dec 15.

84.

Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, Graff BA. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor1. Cancer Res. 2002;62(6):1847-53. Available from: https://cancerres.aacrjournals.org/content/62/6/1847.short.

85.

Maity A, Solomon D. Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. Exp Cell Res. 2000;255:250–7 Academic Press Inc.PubMedCrossRef

86.

Nishi H, Sasaki T, Nagamitsu Y, Terauchi F, Nagai T, Nagao T, et al. Hypoxia inducible factor-1 mediates upregulation of urokinase-type plasminogen activator receptor gene transcription during hypoxia in cervical cancer cells. Oncol Rep. 2016;35:992–8 Spandidos Publications. Available from: https://pubmed.ncbi.nlm.nih.gov/26718775/. Cited 2020 Dec 15.PubMedCrossRef

87.

Trisciuoglio D, Iervolino A, Candiloro A, Fibbi G, Fanciulli M, Zangemeister-Wittke U, et al. bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: Involvement of ERK1/ERK2 activity. J Biol Chem. 2004;279:6737–45 Available from: https://pubmed.ncbi.nlm.nih.gov/14660675/. Cited 2020 Dec 15.PubMedCrossRef

88.

Zeng W, Su J, Wu L, Yang D, Long T, Li D, et al. CD147 Promotes Melanoma Progression Through Hypoxia-Induced MMP2 Activation. Curr Mol Med. 2014;14:163–73 Bentham Science Publishers Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/24090196/. Cited 2020 Dec 15.PubMedCrossRef

89.

Zhang X, Huang Z, Guo Y, Xiao T, Tang L, Zhao S, et al. The phosphorylation of CD147 by Fyn plays a critical role for melanoma cells growth and metastasis. Oncogene. 2020;39:4183–97 Springer Nature. Available from: https://pubmed.ncbi.nlm.nih.gov/32291412/. Cited 2020 Dec 30.PubMedCrossRef

90.

Trisciuoglio D, Desideri M, Ciuffreda L, Mottolese M, Ribatti D, Vacca A, et al. Bcl-2 overexpression in melanoma cells increases tumor progression- associated properties and in vivo tumor growth. J Cell Physiol. 2005;205:414–21 Available from: https://pubmed.ncbi.nlm.nih.gov/15920759/. Cited 2020 Dec 15.PubMedCrossRef

91.

Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, et al. HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest. 2013;123:2078–93 Available from: https://pubmed.ncbi.nlm.nih.gov/23563312/. Cited 2020 Dec 9.PubMedPubMedCentralCrossRef

92.

Steunou AL, Ducoux-Petit M, Lazar I, Monsarrat B, Erard M, Muller C, et al. Identification of the hypoxia-inducible factor 2α nuclear interactome in melanoma cells reveals master proteins involved in melanoma development. Mol Cell Proteomics. 2013;12:736–48 Available from: https://pubmed.ncbi.nlm.nih.gov/23275444/. Cited 2020 Dec 15.PubMedCrossRef

93.

Liu S, Kumar SM, Martin JS, Yang R, Xu X. Snail1 mediates hypoxia-induced melanoma progression. Am J Pathol. 2011;179:3020–31 Available from: https://pubmed.ncbi.nlm.nih.gov/21996677/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

94.

Hao T, Li CX, Ding XY, Xing XJ. MicroRNA-363-3p/p21(Cip1/Waf1) axis is regulated by HIF-2α in mediating stemness of melanoma cells. Neoplasma. 2019;66:427–36 AEPress, s.r.o. Available from: https://pubmed.ncbi.nlm.nih.gov/30784290/. Cited 2020 Dec 15.PubMedCrossRef

95.

Roda JM, Wang Y, Sumner LA, Phillips GS, Marsh CB, Eubank TD. Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol. 2012;189:3168–77 The American Association of Immunologists. Available from: https://pubmed.ncbi.nlm.nih.gov/22869907/. Cited 2020 Dec 15.PubMedCrossRef

96.

Chafe SC, McDonald PC, Saberi S, Nemirovsky O, Venkateswaran G, Burugu S, et al. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol Res. 2019;7:1064–78 American Association for Cancer Research Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/31088846/. Cited 2021 Mar 3.PubMedCrossRef

97.

Pucciarelli D, Lengger N, Takáčová M, Csaderova L, Bartosova M, Breiteneder H, et al. Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib. Mol Med Rep. 2016;13:3281–8 Spandidos Publications. Available from: https://pubmed.ncbi.nlm.nih.gov/26936534/. Cited 2021 Mar 3.PubMedCrossRef

98.

Giuntini G, Monaci S, Cau Y, Mori M, Naldini A, Carraro F. Inhibition of melanoma cell migration and invasion targeting the hypoxic tumor associated caxii. Cancers (Basel). 2020;12:1–15 MDPI AG. Available from: https://pubmed.ncbi.nlm.nih.gov/33080820/. Cited 2021 Mar 3.CrossRef

99.

Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, et al. A MicroRNA signature of hypoxia. Mol Cell Biol. 2007;27:1859–67 American Society for Microbiology. Available from: https://pubmed.ncbi.nlm.nih.gov/17194750/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

100.

Ono S, Oyama T, Lam S, Chong K, Foshag LJ, Hoon DSB. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget. 2015;6:7053–64 Impact Journals LLC. Available from: https://pubmed.ncbi.nlm.nih.gov/25749524/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

101.

Yang X, Lei S, Long J, Liu X, Wu Q. MicroRNA-199a-5p inhibits tumor proliferation in melanoma by mediating HIF-1α. Mol Med Rep. 2016;13:5241–7 Spandidos Publications. Available from: https://pubmed.ncbi.nlm.nih.gov/27122154/. Cited 2020 Dec 15.PubMedCrossRef

102.

Zhao Y, Wu C, Li L. MicroRNA-33b inhibits cell proliferation and glycolysis by targeting hypoxia-inducible factor-1α in malignant melanoma. Exp Ther Med. 2017;14:1299–306 Spandidos Publications. Available from: https://pubmed.ncbi.nlm.nih.gov/28781622/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

103.

Chen Y, Cao K, Wangi S, Chen J, He B, He G, et al. MicroRNA-138 suppresses proliferation, invasion and glycolysis in malignant melanoma cells by targeting HIF-1α. Exp Ther Med. 2016;11:2513–8 Spandidos Publications. Available from: https://pubmed.ncbi.nlm.nih.gov/27284341/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

104.

Zhou J, Xu D, Xie H, Tang J, Liu R, Li J, et al. miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α. Cancer Biol Ther. 2015;16:846–55 Taylor and Francis Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/25891797/. Cited 2020 Dec 16.PubMedPubMedCentralCrossRef

105.

Nagao A, Kobayashi M, Koyasu S, Chow CCT, Harada H. HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. Int J Mol Sci. 2019; MDPI AG. Available from: https://pubmed.ncbi.nlm.nih.gov/30634433/. Cited 2020 Dec 15.

106.

Koch A, Ebert EV, Seitz T, Dietrich P, Berneburg M, Bosserhoff A, et al. Characterization of glycolysis-related gene expression in malignant melanoma. Pathol Res Pract. 2020;216 Elsevier GmbH. Available from: https://pubmed.ncbi.nlm.nih.gov/31791701/. Cited 2020 Dec 15.

107.

Liu H, He Z, Simon HU. Targeting autophagy as a potential therapeutic approach for melanoma therapy. Semin Cancer Biol. 2013:352–60 Available from: https://pubmed.ncbi.nlm.nih.gov/23831275/. Cited 2020 Dec 16.

108.

Lee SJ, Kim HP, Jin Y, Choi AMK, Ryter SW. Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis. Autophagy. 2011;7:829–39 Taylor and Francis Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/21685724/. Cited 2021 Mar 3.PubMedPubMedCentralCrossRef

109.

Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, et al. Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res. 2011;71:5976–86 Available from: https://pubmed.ncbi.nlm.nih.gov/21810913/. Cited 2021 Mar 3.PubMedCrossRef

110.

Fernández-Barral A, Orgaz JL, Gomez V, del Peso L, Calzada MJ, Jiménez B. Hypoxia negatively regulates antimetastatic PEDF in melanoma cells by a hypoxia inducible factor-independent, autophagy dependent mechanism. PLoS One. 2012;7 Available from: https://pubmed.ncbi.nlm.nih.gov/22457728/. Cited 2021 Mar 3.

111.

Sivridis E, Koukourakis MI, Mendrinos SE, Karpouzis A, Fiska A, Kouskoukis C, et al. Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1. Melanoma Res. 2011;21:188–95 Available from: https://pubmed.ncbi.nlm.nih.gov/21537144/. Cited 2020 Dec 15.PubMedCrossRef

112.

Bedogni B, Powell MB. Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Res. 2009;22:166–74 Available from: http://doi.wiley.com/10.1111/j.1755-148X.2009.00553.x. Cited 2021 Mar 3.PubMedPubMedCentralCrossRef

113.

Murphy M, Phelps A, Swede H, Claffey K. Hypoxia-induced response of cell cycle and apoptosis regulators in melanoma. Int J Dermatol. 2012:1263–7 Available from: https://pubmed.ncbi.nlm.nih.gov/22994674/. Cited 2021 Mar 3.

114.

Mo J, Sun B, Zhao X, Gu Q, Dong X, Liu Z, et al. Hypoxia-induced senescence contributes to the regulation of microenvironment in melanomas. Pathol Res Pract. 2013;209:640–7 Available from: https://pubmed.ncbi.nlm.nih.gov/23938031/. Cited 2021 Mar 3.PubMedCrossRef

115.

Almeida FV, Douglass SM, Fane ME, Weeraratna AT. Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma. Pigment Cell Melanoma Res. 2019:237–47 Blackwell Publishing Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/30216694/. Cited 2021 Mar 3.

116.

Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, et al. Hypoxia-driven mechanism of vemurafenib resistance in melanoma. Mol Cancer Ther. 2016;15:2442–54 American Association for Cancer Research Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/27458138/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

117.

Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation. J Exp Med. 2014;211:781–90 Rockefeller University Press. Available from: https://pubmed.ncbi.nlm.nih.gov/24778419/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

118.

Zhang H, Wong CCL, Wei H, Gilkes DM, Korangath P, Chaturvedi P, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene. 2012;31:1757–70 Available from: https://pubmed.ncbi.nlm.nih.gov/21860410/. Cited 2020 Dec 9.PubMedCrossRef

119.

Liu Y, Tao J, Li Y, Yang J, Yu Y, Wang M, et al. Targeting hypoxia-inducible factor-1α with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth. Mol Ther. 2009;17:269–77 Available from: https://pubmed.ncbi.nlm.nih.gov/19066596/. Cited 2020 Dec 15.PubMedCrossRef

120.

Wang Y, Ma J, Yan X, Chen X, Si L, Liu Y, et al. Isoliquiritigenin inhibits proliferation and induces apoptosis via alleviating hypoxia and reducing glycolysis in mouse melanoma B16F10 cells. Recent Pat Anticancer Drug Discov. 2016;11:215–27 Bentham Science Publishers Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/26951491/. Cited 2020 Dec 15.PubMedCrossRef

121.

Alqathama A, Prieto JM. Natural products with therapeutic potential in melanoma metastasis. Nat Prod Rep. 2015;32:1170–82 Royal Society of Chemistry. Available from: https://pubmed.ncbi.nlm.nih.gov/26018751/. Cited 2020 Dec 15.PubMedCrossRef

122.

Li C, Wang Q, Shen S, Wei X, Li G. HIF-1α/VEGF signaling-mediated epithelial–mesenchymal transition and angiogenesis is critically involved in anti-metastasis effect of luteolin in melanoma cells. Phyther Res. 2019;33:798–807 John Wiley and Sons Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/30653763/. Cited 2020 Dec 16.CrossRef

123.

Park EJ, Lee YM, Oh TI, Kim BM, Lim BO, Lim JH. Vanillin suppresses cell motility by inhibiting STAT3-mediated HIF-1α mRNA expression in malignant melanoma cells. Int J Mol Sci. 2017;18 MDPI AG. Available from: https://pubmed.ncbi.nlm.nih.gov/28257048/. Cited 2020 Dec 15.

124.

Lacal PM, Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacol Res. 2018:97–107 Academic Press. Available from: https://pubmed.ncbi.nlm.nih.gov/30170190/. Cited 2020 Dec 30.

125.

Graziani G, Ruffini F, Tentori L, Scimeca M, Dorio AS, Atzori MG, et al. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding. Oncotarget. 2016;7:72868–85 Impact Journals LLC. Available from: https://pubmed.ncbi.nlm.nih.gov/27655684/. Cited 2020 Dec 30.PubMedPubMedCentralCrossRef

126.

Lacal PM, Atzori MG, Ruffini F, Scimeca M, Bonanno E, Cicconi R, et al. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma. Pharmacol Res. 2020;159 Academic Press. Available from: https://pubmed.ncbi.nlm.nih.gov/32485280/. Cited 2020 Dec 15.

127.

Sun S, Zhang J, Wang N, Kong X, Fu F, Wang H, et al. Design and discovery of quinazoline- and thiourea-containing sorafenib analogs as EGFR and VEGFR-2 dual TK inhibitors. Molecules. 2018;23 MDPI AG. Available from: https://pubmed.ncbi.nlm.nih.gov/29295519/. Cited 2020 Dec 30.

128.

Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, et al. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle. 2014;13:2542–53 Landes Bioscience. Available from: https://pubmed.ncbi.nlm.nih.gov/25486195/. Cited 2020 Dec 30.PubMedPubMedCentralCrossRef

129.

Ruma IMW, Putranto EW, Kondo E, Watanabe R, Saito KEN, Inoue Y, et al. Extract of Cordyceps militaris inhibits angiogenesis and suppresses tumor growth of human malignant melanoma cells. Int J Oncol. 2014;45:209–18 Spandidos Publications. Available from: https://pubmed.ncbi.nlm.nih.gov/24789042/. Cited 2020 Dec 30.PubMedCrossRef

130.

Kinet V, Nguyen NQN, Sabatel C, Blacher S, Noël A, Martial JA, et al. Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer Lett. 2009;284:222–8 Available from: https://pubmed.ncbi.nlm.nih.gov/19473755/. Cited 2020 Dec 30.PubMedCrossRef

131.

Fu Y, Rathod D, Patel K. Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma. Exp Cell Res. 2020;396 Elsevier Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/32898554/. Cited 2020 Dec 15.

132.

Bhattacharyya S, Mitra D, Ray S, Biswas N, Banerjee S, Majumder B, et al. Reversing effect of Lupeol on vasculogenic mimicry in murine melanoma progression. Microvasc Res. 2019;121:52–62 Academic Press Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/30381268/. Cited 2020 Dec 15.PubMedCrossRef

133.

Liu ZJL, Zhou YJ, Ding RL, Xie F, Fu SZ, Wu JB, et al. In vitro and in vivo apatinib inhibits vasculogenic mimicry in melanoma MUM-2B cells. PLoS One. 2018;13 Public Library of Science. Available from: https://pubmed.ncbi.nlm.nih.gov/30052652/. Cited 2020 Dec 15.

134.

Shi X, Chen Z, Wang Y, Guo Z, Wang X. Hypotoxic copper complexes with potent anti-metastatic and anti-angiogenic activities against cancer cells. Dalton Trans. 2018;47:5049–5054. Royal Society of Chemistry. Available from: https://pubmed.ncbi.nlm.nih.gov/29561011/. Cited 2020 Dec 15

135.

Itzhaki O, Greenberg E, Shalmon B, Kubi A, Treves AJ, Shapira-Frommer R, et al. Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS One. 2013;8 Available from: https://pubmed.ncbi.nlm.nih.gov/23451174/. Cited 2020 Dec 15.

136.

Liu R, Cao Z, Tu J, Pan Y, Shang B, Zhang G, et al. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment Cell Melanoma Res. 2012;25:630–8 Available from: https://pubmed.ncbi.nlm.nih.gov/22781316/. Cited 2020 Dec 15.PubMedCrossRef

137.

Hendrix MJC, Seftor EA, Seftor REB, Chao JT, Chien DS, Chu YW. Tumor cell vascular mimicry: novel targeting opportunity in melanoma. Pharmacol Ther. 2016:83–92 Elsevier Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/26808163/. Cited 2020 Dec 15.

138.

Felcht M, Thomas M. Angiogenese beim malignen Melanom. JDDG - J Ger Soc Dermatology. 2015:125–35 Wiley-VCH Verlag. Available from: https://pubmed.ncbi.nlm.nih.gov/25631130/. Cited 2020 Dec 15.

139.

Fane ME, Ecker BL, Kaur A, Marino GE, Alicea GM, Douglass SM, et al. sFRP2 supersedes VEGF as an age-related driver of angiogenesis in melanoma, affecting response to anti-VEGF therapy in older patients. Clin Cancer Res. 2020;26:5709–19 American Association for Cancer Research (AACR). Available from: https://pubmed.ncbi.nlm.nih.gov/33097493/. Cited 2020 Dec 15.PubMedPubMedCentralCrossRef

140.

Markovic SN, Suman VJ, Javed A, Reid JM, Wall DJ, Erickson LA, et al. Sequencing ipilimumab immunotherapy before or after chemotherapy (Nab-Paclitaxel and Bevacizumab) for the treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU261206I. Am J Clin Oncol Cancer Clin Trials. 2020;43:115–21 Lippincott Williams and Wilkins. Available from: https://pubmed.ncbi.nlm.nih.gov/31809326/. Cited 2020 Dec 15.

141.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, et al. Corrigendum: adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (Annals of Oncology (2018) 29:8 (1843–1852) DOI: 10.1093/annonc/mdy229). Ann Oncol. 2019:2013–4 Oxford University Press. Available from: https://pubmed.ncbi.nlm.nih.gov/31430371/. Cited 2020 Dec 15.

142.

Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, et al. A phase 2 trial of bevacizumab and high-dose interferon alpha 2b in metastatic melanoma. J Immunother. 2011;34:509–15 Available from: https://pubmed.ncbi.nlm.nih.gov/21654521/. Cited 2020 Dec 21.PubMedPubMedCentralCrossRef

143.

McWilliams RR, Allred JB, Slostad JA, Katipamula R, Dronca RS, Rumilla KM, et al. NCCTG N0879 (Alliance): a randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma. Cancer. 2018;124:537–45 John Wiley and Sons Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/29044496/. Cited 2020 Dec 21.PubMedCrossRef

144.

Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, et al. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer. 2014;50:2099–107 Elsevier Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/24930625/. Cited 2020 Dec 30.PubMedPubMedCentralCrossRef

145.

Fruehauf JP, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz JG. Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2018;82:353–60 Springer Verlag. Available from: https://pubmed.ncbi.nlm.nih.gov/29943192/. Cited 2020 Dec 21.PubMedPubMedCentralCrossRef

146.

Tarhini AA, Frankel P, Margolin KA, Christensen S, Ruel C, Shipe-Spotloe J, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011;17 Available from: http://clincancerres.aacrjournals.org/. Cited 2020 Aug 22.

147.

Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, et al. NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018;124:4332–41 John Wiley and Sons Inc. Available from: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.31734. Cited 2020 Dec 21.

148.

Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res. 2004;14:57–62 Lippincott Williams and Wilkins. Available from: https://pubmed.ncbi.nlm.nih.gov/15091195/. Cited 2020 Dec 21.PubMedCrossRef

149.

Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, et al. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer. 2010;116:424–31 Available from: https://pubmed.ncbi.nlm.nih.gov/19918923/. Cited 2020 Dec 21.PubMedCrossRef

150.

Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, et al. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Chemotherapy. 2009;55:221–7 Available from: https://pubmed.ncbi.nlm.nih.gov/19451711/. Cited 2020 Dec 21.PubMedCrossRef

151.

Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, et al. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer. 2010;116:146–54.PubMed

152.

Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, et al. Phase i safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res. 2010;20:501–6 Available from: https://pubmed.ncbi.nlm.nih.gov/20859231/. Cited 2020 Dec 30.PubMedCrossRef

153.

Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, et al. Phase i clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Investig New Drugs. 2014;32:279–86 Kluwer Academic Publishers. Available from: https://pubmed.ncbi.nlm.nih.gov/23756764/. Cited 2020 Dec 30.CrossRef

154.

McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, et al. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol. 2004;122:400–5 Blackwell Publishing Inc; Available from: https://pubmed.ncbi.nlm.nih.gov/15009722/. Cited 2020 Dec 20.PubMedCrossRef

155.

Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, et al. Phase I/II trial of imatinib and bevacizumab in patients with advanced melanoma and other advanced cancers. Oncologist. 2015;20:952–9 Wiley. Available from: https://pubmed.ncbi.nlm.nih.gov/26084808/. Cited 2020 Dec 21.PubMedPubMedCentralCrossRef

156.

Ugurel S, Hildenbrand R, Zimpfer A, La Rosée P, Paschka P, Sucker A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer. 2005;92:1398–405 Available from: https://pubmed.ncbi.nlm.nih.gov/15846297/. Cited 2020 Dec 21.PubMedPubMedCentralCrossRef

157.

Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327–34 Available from: https://pubmed.ncbi.nlm.nih.gov/21642685/. Cited 2020 Dec 22.PubMedPubMedCentralCrossRef

158.

Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008;99:734–40.PubMedPubMedCentralCrossRef

159.

Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, et al. Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase ii team trial. Ann Oncol. 2017;28:1380–7 Oxford University Press. Available from: https://pubmed.ncbi.nlm.nih.gov/28327988/. Cited 2020 Dec 21.PubMedPubMedCentralCrossRef

160.

Minor DR, Kashani-Sabet M, Garrido M, O’Day SJ, Hamid O, Bastian BC. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012;18:1457–63.PubMedCrossRef

161.

Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011;17:7462–9 Available from: https://pubmed.ncbi.nlm.nih.gov/21976544/. Cited 2020 Dec 5.PubMedCrossRef

162.

Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, et al. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: Results of a clinical/correlative prospective phase II clinical trial. Br J Cancer. 2015;112:1326–31 Nature Publishing Group. Available from: /pmc/articles/PMC4402449/?report=abstract. Cited 2020 Dec 21.PubMedPubMedCentralCrossRef

163.

Cui C, Mao L, Chi Z, Si L, Sheng X, Kong Y, et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of endostar in patients with metastatic melanoma. Mol Ther. 2013;21:1456–63 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/23670576/. Cited 2020 Dec 21.PubMedPubMedCentralCrossRef

164.

Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan PD, Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I, James MG, Strauss UP, Prendergast S, Gore ME. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer. 2011;105(3):353-9. https://doi.org/10.1038/bjc.2011.257.

165.

Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL, Othus M, et al. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res. 2012;18:1129–37 Available from: https://pubmed.ncbi.nlm.nih.gov/22228638/. Cited 2020 Dec 22.PubMedPubMedCentralCrossRef

166.

Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita A, et al. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2014;74:77–84 Springer Verlag. Available from: https://pubmed.ncbi.nlm.nih.gov/24817603/. Cited 2020 Dec 22.PubMedCrossRef

167.

Temozolomide and sorafenib in treating patients with metastatic or unresectable melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00602576?term=NCT00602576&draw=2&rank=1. Cited 2020 Dec 30

168.

Combined treatment of sorafenib and pegylated interferon α2b in stage IV metastatic melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00623402?term=NCT00623402&draw=2&rank=1. Cited 2020 Dec 30

169.

Lenalidomide in combination with bevacizumab, sorafenib, temsirolimus, or 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01183663?term=NCT01183663&draw=2&rank=1. Cited 2020 Dec 30

170.

Temozolomide and thalidomide in treating patients with brain metastases secondary to melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00072163?term=NCT00072163&draw=2&rank=1. Cited 2020 Dec 30

171.

Temozolomide and thalidomide in treating patients with stage III or stage IV melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00005815?term=NCT00005815&draw=2&rank=1. Cited 2020 Dec 30

172.

S0508: thalidomide and temozolomide in treating patients with stage IV melanoma that cannot be removed by surgery - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00104988?term=NCT00104988&draw=2&rank=1. Cited 2020 Dec 30

173.

Temozolomide, thalidomide, and lomustine in treating patients with unresectable stage III or stage IV melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00072345?term=NCT00072345&draw=2&rank=1. Cited 2020 Dec 30

174.

Temozolomide, thalidomide, and lomustine (TTL) in melanoma patients - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00527657?term=NCT00527657&draw=2&rank=1. Cited 2020 Dec 30

175.

Thalidomide and SU5416 in treating patients with metastatic melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00017316?term=NCT00017316&draw=2&rank=1. Cited 2020 Dec 30

176.

Interferon Alfa and thalidomide in treating patients with stage IV melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00026520?term=NCT00026520&draw=2&rank=1. Cited 2020 Dec 30

177.

PEG-Interferon Alfa-2b and thalidomide in treating patients with recurrent or metastatic melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00238329?term=NCT00238329&draw=2&rank=1. Cited 2020 Dec 30

178.

Thalidomide and dacarbazine for metastatic melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00006200?term=NCT00006200&draw=2&rank=1. Cited 2020 Dec 30

179.

Ipilimumab with or without bevacizumab in treating patients with stage III-IV melanoma that cannot be removed by surgery - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01950390?term=NCT01950390&draw=2&rank=1. Cited 2020 Dec 30

180.

Bevacizumab plus ipilimumab in patients with unresectable stage III or IV melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00790010?term=bevacizumab+ipilimumab&cond=Cutaneous+Melanoma&draw=2. Cited 2020 Dec 21

181.

Pembrolizumab and Ziv-aflibercept in treating patients with advanced solid tumors - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02298959?term=NCT02298959&draw=2&rank=1. Cited 2020 Dec 30

182.

Sunitinib in treating patients with brain metastases caused by kidney cancer or melanoma - Full Text View - ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT00462982?term=NCT00462982&draw=2&rank=1. Cited 2020 Dec 30

183.

Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma (The MATCH Screening Trial) - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&draw=2&rank=1. Cited 2020 Dec 30

184.

Trial of imatinib (Gleevec®) in selected patients with metastatic melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00881049?term=NCT00881049&draw=2&rank=1. Cited 2020 Dec 30

185.

Phase II study of imatinib mesylate in patients with life threatening malignant rare diseases - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00154388?term=NCT00154388&draw=2&rank=1. Cited 2020 Dec 30

186.

Imatinib mesylate in combination with pembrolizumab in patients with melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04546074?term=NCT04546074&draw=2&rank=1. Cited 2020 Dec 30

187.

Binimetinib and imatinib for unresectable stage III-IV KIT-mutant melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04598009?term=NCT04598009&draw=2&rank=1. Cited 2020 Dec 30

188.

Nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04493203?term=NCT04493203&draw=2&rank=1. Cited 2020 Dec 30

189.

Tolerability and pharmacokinetics of toripalimab in combination with axitinib in patients with kidney cancer and melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03086174?term=NCT03086174&draw=2&rank=1. Cited 2020 Dec 30

190.

Nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04091750?term=NCT04091750&draw=2&rank=1. Cited 2020 Dec 30

191.

Cabozantinib and pembrolizumab for advanced metastatic melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03957551?term=NCT03957551&draw=2&rank=1. Cited 2020 Dec 30

192.

Testing the combination of the anti-cancer drugs XL184 (Cabozantinib) and nivolumab in patients with advanced cancer and HIV - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04514484?term=NCT04514484&draw=2&rank=1. Cited 2020 Dec 30

193.

Tarhini AA, Frankel P, Margolin KA, Christensen S, Ruel C, Shipe-Spotloe J, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011;17:6574–81 Available from: https://pubmed.ncbi.nlm.nih.gov/21880788/. [cited 2020 Dec 5].PubMedPubMedCentralCrossRef

194.

Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32:1363–72 Available from: https://pubmed.ncbi.nlm.nih.gov/22466491/. Cited 2020 Aug 22.PubMedCrossRef

195.

Brouwer NJ, Gezgin G, Wierenga APA, Bronkhorst IHG, Marinkovic M, Luyten GPM, et al. Tumour angiogenesis in uveal melanoma is related to genetic evolution. Cancers (Basel). 2019;11 MDPI AG. Available from: https://pubmed.ncbi.nlm.nih.gov/31337000/. Cited 2020 Dec 9.

196.

Nabil AA, Marie S, Marc-Henri S, Nathalie C, Laurence D, Sophie PN, et al. Upcoming translational challenges for uveal melanoma. Br J Cancer. 2015:1249–53 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/26505679/. Cited 2020 Dec 9.

197.

Onken MD, Li J, Cooper JA. Uveal melanoma cells utilize a novel route for transendothelial migration. PLoS One. 2014;9 Public Library of Science. Available from: https://pubmed.ncbi.nlm.nih.gov/25506912/. Cited 2020 Dec 9.

198.

Obenauf AC, Massagué J. Surviving at a distance: organ-specific metastasis. Trends Cancer. 2015:76–91 Cell Press. Available from: https://pubmed.ncbi.nlm.nih.gov/28741564/. Cited 2020 Dec 14.

199.

Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36:109–40 Springer New York LLC. Available from: https://pubmed.ncbi.nlm.nih.gov/28229253/.Cited 2020 Dec 14.PubMedPubMedCentralCrossRef

200.

Royer-Bertrand B, Torsello M, Rimoldi D, El Zaoui I, Cisarova K, Pescini-Gobert R, et al. Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. Am J Hum Genet. 2016;99:1190–8 Cell Press. Available from: https://pubmed.ncbi.nlm.nih.gov/27745836/. Cited 2020 Dec 14.PubMedPubMedCentralCrossRef

201.

Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599–602.PubMedCrossRef

202.

Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191–9 Massachussetts Medical Society.PubMedPubMedCentralCrossRef

203.

Shields CL, Kaliki S, Livesey M, Walker B, Garoon R, Bucci M, et al. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis analysis of 7872 consecutive eyes. JAMA Ophthalmol. 2013;131:993–1003 Available from: https://pubmed.ncbi.nlm.nih.gov/23681424/. Cited 2020 Aug 22.PubMedCrossRef

204.

Singh AD, De Potter P, Fijal BA, Shields CL, Shields JA, Elston RC. Lifetime prevalence of uveal melanoma in white patients with oculo (dermal) melanocytosis. Ophthalmology. 1998;105:195–8 Elsevier Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/9442799/. Cited 2020 Aug 22.PubMedCrossRef

205.

Hammer H, Oláh J, Tóth-Molnár E. Dysplastic nevi are a risk factor for uveal melanoma. Eur J Ophthalmol. 1996;6:472–4 Wichtig Editore s.r.l. Available from: http://journals.sagepub.com/doi/10.1177/112067219600600423. Cited 2020 Aug 22.PubMedCrossRef

206.

McDonald KA, Krema H, Chan A-W. Cutaneous signs and risk factors for ocular melanoma. J Am Acad Dermatol. 2020; Mosby. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0190962220324968. Cited 2020 Sep 11.

207.

Barker CA, Salama AK. New NCCN guidelines for uveal melanoma and treatment of recurrent or progressive distant metastatic melanoma. J Natl Compr Cancer Netw. 2018:646–50 Harborside Press.

208.

McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000–7 Available from: https://pubmed.ncbi.nlm.nih.gov/15651058/. Cited 2020 Aug 22.PubMedCrossRef

209.

Singh AD, Turell ME, Topham AK. Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881–5 Available from: https://pubmed.ncbi.nlm.nih.gov/21704381/. Cited 2020 Aug 22.PubMedCrossRef

210.

Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114 Elsevier Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/17498805/. Cited 2020 Aug 22.

211.

Mallone S, De Vries E, Guzzo M, Midena E, Verne J, Coebergh JW, et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer. 2012;48:1167–75 Elsevier Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/22119735/. Cited 2020 Aug 22.PubMedCrossRef

212.

Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2384 patients. Ophthalmology. 2012;119:1582–9 Available from: https://pubmed.ncbi.nlm.nih.gov/22503229/. Cited 2020 Aug 22.PubMedCrossRef

213.

Mahendraraj K, CSM L, Lee I, Chamberlain RS, et al. Clin Ophthalmol. 2016;10:2113–9 Dove Medical Press Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/27822007/. Cited 2020 Aug 22.PubMedPubMedCentralCrossRef

214.

Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973–2013). Ocul Oncol Pathol. 2018;4:145–51 S. Karger AG. Available from: https://pubmed.ncbi.nlm.nih.gov/29765944/. Cited 2020 Aug 22.PubMedCrossRef

215.

Xu Y, Lou L, Wang Y, Miao Q, Jin K, Chen M, et al. Epidemiological study of uveal melanoma from us surveillance, epidemiology, and end results program (2010–2015). J Ophthalmol. 2020;2020 Hindawi Limited. Available from: https://pubmed.ncbi.nlm.nih.gov/32148939/. Cited 2020 Aug 22.

216.

Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 2005;140:612.e1–8 Elsevier Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/16226513/. Cited 2020 Aug 22.CrossRef

217.

Yu G-P, Hu D-N, McCormick SA. Latitude and incidence of ocular melanoma. Photochem Photobiol. 2006;82:1621 Wiley. Available from: https://pubmed.ncbi.nlm.nih.gov/16922607/. Cited 2020 Aug 22.PubMedCrossRef

218.

Shields CL, Kaliki S, Cohen MN, Shields PW, Furuta M, Shields JA. Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture. Eye. 2015;29:1027–35 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/26248525/. Cited 2020 Aug 22.PubMedPubMedCentralCrossRef

219.

Accuracy of diagnosis of choroidal melanomas in the collaborative ocular melanoma study: COMS Report No. 1. Arch Ophthalmol. 1990;108:1268–73 Available from: https://pubmed.ncbi.nlm.nih.gov/2205183/. Cited 2020 Aug 22.

220.

Shields JA, Shields CL, Ehya H, Eagle RC, De Potter P. Fine-needle aspiration biopsy of suspected intraocular tumors. Int Ophthalmol Clin. 1993;33:77–82 Available from: https://pubmed.ncbi.nlm.nih.gov/8407195/. Cited 2020 Aug 22.PubMedCrossRef

221.

Badve SS, Fisher C. AJCC 8th edition—A step forward. Breast J. 2020;26(7):1263-4. Blackwell Publishing Inc.

222.

Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98.PubMedCrossRef

223.

Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields JA. American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. Ophthalmology. 2013;120:2066–71 Available from: https://pubmed.ncbi.nlm.nih.gov/23664467/. Cited 2020 Aug 22.PubMedCrossRef

224.

Gill HS, Char DH. Uveal melanoma prognostication: From lesion size and cell type to molecular class. Can J Ophthalmol. 2012;47:246–53 Elsevier B.V. Available from: https://pubmed.ncbi.nlm.nih.gov/22687301/. Cited 2020 Aug 22.PubMedCrossRef

225.

Bagger M, Andersen MT, Andersen KK, Heegaard S, Kiilgaard JF. The prognostic effect of American joint committee on cancer staging and genetic status in patients with choroidal and ciliary body melanoma. Investig Ophthalmol Vis Sci. 2015;56:438–44.CrossRef

226.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin Am Cancer Soc. 2017;67:93–9.CrossRef

227.

Aalto Y, Eriksson L, Science SS- … & visual, 2001 undefined. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. iovs.arvojournals.org. Available from: https://iovs.arvojournals.org/article.aspx?articleid=2123333. Cited 2020 Aug 22

228.

Ewens KG, Kanetsky PA, Richards-Yutz J, Al-Dahmash S, de Luca MC, Bianciotto CG, et al. Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome. Investig Ophthalmol Vis Sci. 2013;54:5721–9 Available from: https://pubmed.ncbi.nlm.nih.gov/23821189/. Cited 2020 Aug 22.CrossRef

229.

Hawkins BS. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006;124:1684–93 Available from: https://pubmed.ncbi.nlm.nih.gov/17159027/. Cited 2020 Aug 22.CrossRef

230.

Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Investig Ophthalmol Vis Sci. 2003;44:4651–9 Available from: https://pubmed.ncbi.nlm.nih.gov/14578381/. Cited 2020 Aug 22.CrossRef

231.

Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, et al. Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist. 2016;21:848–54 Wiley. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27286787. Cited 2020 Aug 22.PubMedPubMedCentralCrossRef

232.

Van Der Kooij MK, Speetjens FM, Van Der Burg SH, Kapiteijn E. Cancers uveal versus cutaneous melanoma; same origin, very distinct tumor types. mdpi.com. 2019;11 MDPI AG. Available from: www.mdpi.com/journal/cancers. Cited 2020 Aug 22.

233.

Seibel I, Cordini D, Rehak M, Hager A, Riechardt AI, Böker A, et al. Local recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches, and outcome. Am J Ophthalmol. 2015;160:628–36 Elsevier Inc.PubMedCrossRef

234.

Coupland SE, Sidiki S, Clark BJ, McClaren K, Kyle P, Lee WR. Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. Arch Ophthalmol American Medical Association. 1996;114:751–6.CrossRef

235.

Shields JA, Augsburger JJ, Donoso LA, Bernardino VB, Portenar M. Hepatic metastasis and orbital recurrence of uveal melanoma after 42 years. Am J Ophthalmol. 1985;100:666–8 Available from: https://pubmed.ncbi.nlm.nih.gov/4061546/. Cited 2020 Aug 22.PubMedCrossRef

236.

Kivelä T, Suciu S, Hansson J, … WK-EJ of, 2003 undefined. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Elsevier. Available from: https://www.sciencedirect.com/science/article/pii/S0959804903001321. Cited 2020 Aug 22

237.

Homsi J, Bedikian A, … NP-M, 2010 undefined. Phase 2 open-label study of weekly docosahexaenoic acid–paclitaxel in patients with metastatic uveal melanoma. journals.lww.com. Available from: https://journals.lww.com/melanomaresearch/Fulltext/2010/12000/Phase_2_open_label_study_of_weekly_docosahexaenoic.10.aspx.Cited 2020 Aug 22

238.

Schmittel A, Scheulen M, … NB-M, 2005 undefined. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. journals.lww.com. Available from: https://journals.lww.com/melanomaresearch/Fulltext/2005/06000/Phase_II_trial_of_cisplatin,_gemcitabine_and.10.aspx. Cited 2020 Aug 22

239.

Mallone F, Sacchetti M, Lambiase A, Moramarco A. Molecular insights and emerging strategies for treatment of metastatic uveal melanoma. Cancers (Basel). 2020:1–29 MDPI AG. Available from: https://pubmed.ncbi.nlm.nih.gov/32992823/. Cited 2021 Mar 3.

240.

Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32:204–220.e15 Cell Press. Available from: https://pubmed.ncbi.nlm.nih.gov/28810145/. cited 2020 Aug 22.PubMedPubMedCentralCrossRef

241.

Dong L, You S, Zhang Q, Osuka S, Devi NS, Kaluz S, et al. Arylsulfonamide 64B inhibits hypoxia/ HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma. Clin Cancer Res. 2019;25:2206–18 American Association for Cancer Research Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/30563937/.Cited 2020 Dec 9.PubMedCrossRef

242.

El Filali M, Missotten GSOA, Maat W, Ly LV, Luyten GPM, van der Velden PA, et al. Regulation of VEGF-A in uveal melanoma. Investig Ophthalmol Vis Sci. 2010;51:2329–37 Available from: https://pubmed.ncbi.nlm.nih.gov/20042655/. Cited 2020 Dec 9.CrossRef

243.

Victor N, Ivy A, Jiang BH, Agani FH. Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells. Clin Exp Metastasis. 2006;23:87–96 Available from: https://pubmed.ncbi.nlm.nih.gov/16826425/. Cited 2020 Dec 9.PubMedCrossRef

244.

Giatromanolaki A, Sivridis E, Bechrakis NE, Willerding G, St. Charitoudis G, Foerster MH, et al. Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival. Clin Exp Metastasis. 2012;29:11–7 Available from: https://pubmed.ncbi.nlm.nih.gov/21984395/. Cited 2020 Dec 9.PubMedCrossRef

245.

Chang SH, Worley LA, Onken MD, Harbour JW. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res. 2008;18:191–200 Available from: https://pubmed.ncbi.nlm.nih.gov/18477893/. Cited 2020 Dec 9.PubMedCrossRef

246.

Xu Q, Zhao GQ, Zhao J, Lin H, Mou YY, Wang Q, et al. Expression and significance of factors related to angiogenesis in choroidal melanoma. Int J Ophthalmol. 2011;4:49–54 Available from: https://pubmed.ncbi.nlm.nih.gov/22553608/. Cited 2020 Dec 9.PubMedPubMedCentral

247.

IJland SAJ, Jager MJ, Heijdra BM, Westphal JR, Peek R. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res. 1999;9:445–50 Lippincott Williams and Wilkins. Available from: https://pubmed.ncbi.nlm.nih.gov/10596910/. Cited 2020 Dec 9.PubMedCrossRef

248.

Hu K, Babapoor-Farrokhran S, Rodrigues M, Deshpande M, Puchner B, Kashiwabuchi F, et al. Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma. Oncotarget. 2016;7:7816–28 Impact Journals LLC. Available from: https://pubmed.ncbi.nlm.nih.gov/26761211/. Cited 2020 Dec 9.PubMedPubMedCentralCrossRef

249.

Asnaghi L, Lin MH, Lim KS, Lim KJ, Tripathy A, Wendeborn M, et al. Hypoxia promotes uveal melanoma invasion through enhanced notch and MAPK activation. PLoS One. 2014;9 Available from: https://pubmed.ncbi.nlm.nih.gov/25166211/. Cited 2020 Dec 9.

250.

Asnaghi L, Lin MH, Lim KS, Lim KJ, Bar EE, Eberhart CG. Abstract 3776: Hypoxia-inducible factor 1α (HIF1α) has a prometastatic effect in uveal melanoma. Cancer Res. 2013:3776 American Association for Cancer Research (AACR). Available from: https://cancerres.aacrjournals.org/content/73/8_Supplement/3776. Cited 2020 Dec 9.

251.

Asnaghi L, Handa JT, Merbs SL, Harbour JW, Eberhart CG. A role for Jag2 in promoting uveal melanoma dissemination and growth. Investig Ophthalmol Vis Sci. 2013;54:295–306 Available from: https://pubmed.ncbi.nlm.nih.gov/23211831/. Cited 2020 Dec 9.CrossRef

252.

Xia Z, Yang C, Yang X, Wu S, Feng Z, Qu L, et al. MiR-652 promotes proliferation and migration of uveal melanoma cells by targeting HOXA9. Med Sci Monit. 2019;25:8722–32 International Scientific Information, Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/31740654/. Cited 2021 Mar 3.PubMedPubMedCentralCrossRef

253.

Zhou L, Wang Y, Zhou M, Zhang Y, Wang P, Li X, et al. HOXA9 inhibits HIF-1α-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development. Nat Commun. 2018;9 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/29662084/. Cited 2021 Mar 3.

254.

Castet F, Garcia-Mulero S, Sanz-Pamplona R, Cuellar A, Casanovas O, Caminal JM, et al. Uveal melanoma, angiogenesis and immunotherapy, is there any hope? Cancers (Basel). 2019; MDPI AG. Available from: https://pubmed.ncbi.nlm.nih.gov/31212986/. Cited 2020 Dec 9.

255.

Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003:401–10 Available from: https://pubmed.ncbi.nlm.nih.gov/12778130/. Cited 2020 Dec 9.

256.

Lane AM, Egan KM, Yang J, Saornil MA, Alroy J, Albert D, et al. An evaluation of tumour vascularity as a prognostic indicator in uveal melanoma. Melanoma Res. 1997;7:237–42 Lippincott Williams and Wilkins. Available from: https://pubmed.ncbi.nlm.nih.gov/9195563/. Cited 2020 Dec 9.PubMedCrossRef

257.

Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe’er J, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389–98 Available from: https://pubmed.ncbi.nlm.nih.gov/8371929/. Cited 2020 Dec 9.PubMedCrossRef

258.

Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Investig Ophthalmol Vis Sci. 1999;40:2471–80.

259.

Foss AJE, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S. Microvessel count predicts survival in uveal melanoma1. Cancer Res. 1996;56(13):2900-3. Available from: https://cancerres.aacrjournals.org/content/56/13/2900.short.

260.

Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006:15–26 Available from: https://pubmed.ncbi.nlm.nih.gov/16716598/. Cited 2020 Dec 9.

261.

El Filali M, Van Der Velden PA, Luyten GPM, Jager MJ. Anti-angiogenic therapy in uveal melanoma. Dev Ophthalmol. 2012;49:117–36 Available from: https://pubmed.ncbi.nlm.nih.gov/22042017/. Cited 2020 Dec 9.PubMedCrossRef

262.

Barak V, Pe’er J, Kalickman I, Frenkel S. VEGF as a biomarker for metastatic uveal melanoma in humans. Curr Eye Res. 2011;36:386–90 Available from: https://pubmed.ncbi.nlm.nih.gov/21284506/. Cited 2020 Dec 9.PubMedCrossRef

263.

Yang M, Kuang X, Pan Y, Tan M, Lu B, Lu J, et al. Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: a meta-analysis. Mol Clin Oncol. 2014;2:363–8 Spandidos Publications. Available from: https://pubmed.ncbi.nlm.nih.gov/24772301/. Cited 2020 Dec 9.PubMedPubMedCentralCrossRef

264.

Bronkhorst IHG, Jehs TML, Dijkgraaf EM, Luyten GPM, Van Der Velden PA, Van Der Burg SH, et al. Effect of hypoxic stress on migration and characteristics of monocytes in uveal melanoma. JAMA Ophthalmol. 2014;132:614–21 American Medical Association. Available from: https://pubmed.ncbi.nlm.nih.gov/24626595/. Cited 2020 Dec 9.PubMedCrossRef

265.

Boyd SR, Tan DSW, De Souza L, Neale MH, Myatt NE, Alexander RA, et al. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol. 2002;86:440–7 Available from: https://pubmed.ncbi.nlm.nih.gov/11914215/. Cited 2020 Dec 9.PubMedPubMedCentralCrossRef

266.

Lattanzio L, Tonissi F, Torta I, Gianello L, Russi E, Milano G, et al. Role of IL-8 induced angiogenesis in uveal melanoma. Investig New Drugs. 2013;31:1107–14 Available from: https://pubmed.ncbi.nlm.nih.gov/23912257/. Cited 2020 Dec 9.CrossRef

267.

Midena E, Parrozzani R, Midena G, Trainiti S, Marchione G, Cosmo E, et al. In vivo intraocular biomarkers: changes of aqueous humor cytokines and chemokines in patients affected by uveal melanoma. Medicine (Baltimore). 2020;99:e22091 NLM (Medline). Available from: https://pubmed.ncbi.nlm.nih.gov/32957329/. Cited 2020 Dec 9.CrossRef

268.

Filali M el, Homminga I, … WM-M, 2008 undefined. Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth. ncbi.nlm.nih.gov. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556975/. Cited 2020 Dec 9

269.

Missotten GSO, Notting IC, Schlingemann RO, Zijlmans HJ, Lau C, Eilers PHC, et al. Vascular endothelial growth factor A in eyes with uveal melanoma. Arch Ophthalmol. 2006;124:1428–34 Available from: https://pubmed.ncbi.nlm.nih.gov/17030710/. Cited 2020 Dec 9.PubMedCrossRef

270.

Sheidow TG, Hooper PL, Crukley C, Young J, Heathcote JG. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophthalmol. 2000;84:750–6 Available from: https://pubmed.ncbi.nlm.nih.gov/10873988/.Cited 2020 Dec 9.PubMedPubMedCentralCrossRef

271.

Vinores SA, Kuchle M, Mahlow J, Chiu C, Green WR, Campochiaro PA. Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol. 1995;147(5):1289–97.

272.

Potgens AJG, Lubsen NH, Van Altena MC, Schoenmakers JGG, Ruiter DJ, De Waal RMW. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol. 1995;146:197–209 Available from: https://pubmed.ncbi.nlm.nih.gov/7531947/. Cited 2020 Dec 14.PubMedPubMedCentral

273.

Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo K-T, Manseau EJ, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996;56(1):172-81.

274.

Westphal JR, Van’t Hullenaar RGM, Van der Laak JAWM, Cornelissen IMHA, Schalkwijk LJM, Van Muijen GNP, et al. Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer. 1997;76:561–70 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/9303353/. Cited 2020 Dec 9.PubMedPubMedCentralCrossRef

275.

Nagarkatti-Gude N, Bronkhorst IHG, van Duinen SG, Luyten GPM, Jager MJ. Cytokines and chemokines in the vitreous fluid of eyes with uveal melanoma. Investig Ophthalmol Vis Sci. 2012;53:6748–55 Available from: https://pubmed.ncbi.nlm.nih.gov/22930720/. Cited 2020 Dec 9.CrossRef

276.

Peris-Torres C, Plaza-Calonge MDC, López-Domínguez R, Domínguez-García S, Barrientos-Durán A, Carmona-Sáez P, et al. Extracellular protease adamts1 is required at early stages of human uveal melanoma development by inducing stemness and endothelial-like features on tumor cells. Cancers (Basel). 2020;12 MDPI AG. Available from: https://pubmed.ncbi.nlm.nih.gov/32230715/. Cited 2020 Dec 9.

277.

Stålhammar G, See T, … SP-M, 2019 undefined. Density of PAS positive patterns in uveal melanoma: correlation with vasculogenic mimicry, gene expression class, BAP-1 expression, macrophage infiltration. ncbi.nlm.nih.gov. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776441/. Cited 2020 Dec 9

278.

Cong R, Sun Q, Yang L, Gu H, Zeng Y, Wang B. Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells. J Exp Clin Cancer Res. 2009;28 Available from: https://pubmed.ncbi.nlm.nih.gov/19735546/. Cited 2020 Dec 9.

279.

Seftor REB, Seftor EA, Kirschmann DA, Hendrix MJC.Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther. 2002;1(13):1173–9.

280.

Xu X, Zong Y, Gao Y, Sun X, Zhao H, Luo W, et al. VEGF induce vasculogenic mimicry of choroidal melanoma through the PI3k signal pathway. Biomed Res Int. 2019;2019 Hindawi Limited. Available from: https://pubmed.ncbi.nlm.nih.gov/31380420/. Cited 2020 Dec 9.

281.

Hendrix MJC, Seftor EA, Meltzer PS, Gardner LMG, Hess AR, Kirschmann DA, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry. Proc Natl Acad Sci U S A. 2001;98:8018–23 National Academy of Sciences. Available from: www.nhgri.nih.gov.Cited 2020 Dec 9.PubMedPubMedCentralCrossRef

282.

Liu S, Zhang J, Fang S, Su X, Zhang Q, Zhu G, et al. Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft. Cancer Lett. 2020;495:123–34 Elsevier Ireland Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/32946963/. Cited 2020 Dec 9.PubMedCrossRef

283.

Li W, Zhou Y. LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial–mesenchymal transition. Biosci Rep. 2019;39 Portland Press Ltd, Available from: https://pubmed.ncbi.nlm.nih.gov/30487162/. Cited 2020 Dec 9.

284.

Mäki JM. Lysyl oxidases in mammalian development and certain pathological conditions. Histol Histopathol. 2009:651–60 Available from: https://pubmed.ncbi.nlm.nih.gov/19283672/. Cited 2020 Dec 9.

285.

Benedicto I, Lehmann GL, Ginsberg M, Nolan DJ, Bareja R, Elemento O, et al. Concerted regulation of retinal pigment epithelium basement membrane and barrier function by angiocrine factors. Nat Commun. 2017;8 Nature Publishing Group. Available from: https://pubmed.ncbi.nlm.nih.gov/28524846/. Cited 2020 Dec 9.

286.

Abourbih DA, Di Cesare S, Orellana ME, Antecka E, Martins C, Petruccelli LA, et al. Lysyl oxidase expression and inhibition in uveal melanoma. Melanoma Res. 2010;20:97–106 Available from: https://pubmed.ncbi.nlm.nih.gov/20179655/. Cited 2020 Dec 9.PubMedCrossRef

287.

Noda T, Fujita N, Yoshimori T. The late stages of autophagy: how does the end begin? Cell Death Differ. 2009:984–90 Available from: https://pubmed.ncbi.nlm.nih.gov/19424283/. Cited 2020 Dec 9.

288.

Giatromanolaki AN, St Charitoudis G, Bechrakis NE, Kozobolis VP, Koukourakis MI, Foerster MH, et al. Autophagy patterns and prognosis in uveal melanomas. Mod Pathol. 2011;24:1036–45 Available from: https://pubmed.ncbi.nlm.nih.gov/21499230/. Cited 2020 Dec 9.PubMedCrossRef

289.

Rouschop K, Wouters B. Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr Mol Med. 2009;9:417–24 Bentham Science Publishers Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/19519399/. Cited 2020 Dec 9.PubMedCrossRef

290.

Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouysségur J, et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol. 2009;29:2570–81 American Society for Microbiology. Available from: https://pubmed.ncbi.nlm.nih.gov/19273585/.Cited 2020 Dec 9.PubMedPubMedCentralCrossRef

291.

Zhang H, Bosch-Marce M, Shimoda LA, Yee ST, Jin HB, Wesley JB, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem. 2008;283:10892–903 Available from: https://pubmed.ncbi.nlm.nih.gov/18281291/. Cited 2020 Dec 9.PubMedPubMedCentralCrossRef

292.

Li P, He J, Yang Z, Ge S, Zhang H, Zhong Q, et al. ZNNT1 long noncoding RNA induces autophagy to inhibit tumorigenesis of uveal melanoma by regulating key autophagy gene expression. Autophagy. 2020;16:1186–99 Available from: https://pubmed.ncbi.nlm.nih.gov/31462126/. Taylor and Francis Inc.; [cited 2020 Dec 9].PubMedCrossRef

293.

Truong A, Yoo JH, Scherzer MT, Sanchez JMS, Dale KJ, Kinsey CG, et al. Chloroquine Sensitizes GNAQ/11 -mutated melanoma to MEK1/2 Inhibition. Clin Cancer Res. 2020;26:6374–86 Available from: https://pubmed.ncbi.nlm.nih.gov/32933997/. American Association for Cancer Research (AACR);[cited 2020 Dec 9].PubMedCrossRefPubMedCentral

294.

Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010:12–27 Available from: https://pubmed.ncbi.nlm.nih.gov/19796660/. [cited 2020 Dec 9].

295.

Martens TF, Remaut K, Deschout H, Engbersen JFJ, Hennink WE, Van Steenbergen MJ, et al. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy. J Control Release. 2015;202:83–92 Available from: https://pubmed.ncbi.nlm.nih.gov/25634806/. Elsevier; [cited 2020 Dec 9].PubMedCrossRef

296.

Xie L, Yang Y, Shen J. Efficient inhibition of uveal melanoma via ternary siRNA complexes. Int J Pharm. 2020;573 Available from: https://pubmed.ncbi.nlm.nih.gov/31765784/. Elsevier B.V.; [cited 2020 Dec 9].

297.

Denk AE, Bettstetter M, Wild PJ, Hoek K, Bataille F, Dietmaier W, et al. Loss of maspin expression contributes to a more invasive potential in malignant melanoma. Pigment Cell Res. 2007;20:112–9 Available from: https://pubmed.ncbi.nlm.nih.gov/17371437/. [cited 2020 Dec 9].PubMedCrossRef

298.

Chua R, Setzer S, Govindarajan B, Sexton D, Cohen C, Arbiser JL. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J Am Acad Dermatol. 2009;60:758–66 Available from: https://pubmed.ncbi.nlm.nih.gov/19389518/. [cited 2020 Dec 9].PubMedCrossRef

299.

Fodor K, Dobos N, Schally A, Steiber Z, Olah G, Sipos E, et al. The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma. Oncotarget. 2020;11:175–87 Available from: https://pubmed.ncbi.nlm.nih.gov/32010430/. Impact Journals LLC; [cited 2020 Dec 9].PubMedPubMedCentralCrossRef

300.

Treszl A, Steiber Z, Schally AV, Block NL, Dezso B, Olah G, et al. Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma. Oncotarget. 2013;4:1721–8 Available from: https://pubmed.ncbi.nlm.nih.gov/24077773/. Impact Journals LLC; [cited 2020 Dec 9].PubMedPubMedCentralCrossRef

301.

Oláh G, Dobos N, Vámosi G, Szabó Z, Sipos É, Fodor K, et al. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152). Eur J Pharm Sci. 2018;123:371–6 Available from: https://pubmed.ncbi.nlm.nih.gov/30076951/. Elsevier B.V.; [cited 2020 Dec 9].PubMedCrossRef

302.

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, et al. Phase i, dose-escalation study of the targeted cytotoxic lhrh analog aezs-108 in patients with castration- And taxane-resistant prostate cancer. Clin Cancer Res. 2014;20:6277–83 Available from: https://pubmed.ncbi.nlm.nih.gov/25278449/. American Association for Cancer Research Inc.; [cited 2020 Dec 9].PubMedCrossRef

303.

Engel J, Emons G, Pinski J, Schally AV. AEZS-108: A targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs. 2012:891–9 Available from: https://www.tandfonline.com/doi/abs/10.1517/13543784.2012.685128. Taylor & Francis; [cited 2020 Dec 9].

304.

Mooring SR, Jin H, Devi NS, Jabbar AA, Kaluz S, Liu Y, et al. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. J Med Chem. 2011;54:8471–89 Available from: https://pubmed.ncbi.nlm.nih.gov/22032632/. [cited 2020 Dec 9].PubMedPubMedCentralCrossRef

305.

Li H, Yang W, Chen PW, Alizadeh H, Niederkorn JY. Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases. Investig Ophthalmol Vis Sci. 2009;50:5522–8 Available from: https://pubmed.ncbi.nlm.nih.gov/19553629/. [cited 2020 Dec 9].CrossRef

306.

Bi J, Li P, Li C, He J, Wang Y, Zhang H, et al. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration. Tumor Biol. 2016;37:4175–82 Available from: https://pubmed.ncbi.nlm.nih.gov/26490988/. Springer Netherlands; [cited 2020 Dec 9].CrossRef

307.

van den Bosch T, Koopmans AE, Vaarwater J, van den Berg M, de Klein A, Verdijk RM. Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance. Investig Ophthalmol Vis Sci. 2013;54:7354–61 Available from: https://pubmed.ncbi.nlm.nih.gov/24052640/. [cited 2020 Dec 9].CrossRef

308.

Gardner FP, Serie DJ, Salomao DR, Wu KJ, Markovic SN, Pulido JS, et al. C-MET expression in primary and liver metastases in uveal melanoma. Melanoma Res. 2014;24:617–20 Available from: https://pubmed.ncbi.nlm.nih.gov/25211165/. Lippincott Williams and Wilkins; [cited 2020 Dec 9].PubMedCrossRef

309.

Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One. 2014;9 Available from: https://pubmed.ncbi.nlm.nih.gov/24551032/. Public Library of Science; [cited 2020 Dec 9].

310.

Liepelt A, Tacke F. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases. Am J Physiol - Gastrointest Liver Physiol. 2016:G203–9 Available from: https://pubmed.ncbi.nlm.nih.gov/27313175/. American Physiological Society;[cited 2020 Dec 9].

311.

Shneor D, Tayeb S, Pe’er J, Voropaev H, Gimmelshein M, Cassoux N, et al. A novel combinatorial treatment option for metastatic uveal melanoma. Oncotarget. 2018;9:26096–108 Available from: https://pubmed.ncbi.nlm.nih.gov/29899845/. Impact Journals LLC;[cited 2020 Dec 9].PubMedPubMedCentralCrossRef

312.

Liu Y, Huo Y, Wang D, Tai Y, Li J, Pang D, et al. MiR-216a-5p/Hexokinase 2 axis regulates uveal melanoma growth through modulation of Warburg effect. Biochem Biophys Res Commun. 2018;501:885–92 Elsevier B.V.PubMedCrossRef

313.

Voropaev H, Gimmelshein Vatkin M, Shneor D, Luski S, Honigman A, Frenkel S. Infectious knockdown of CREB and HIF-1 for the treatment of metastatic uveal melanoma. Cancers (Basel). 2019;11:1056 Available from: https://www.mdpi.com/2072-6694/11/8/1056. MDPI AG; [cited 2020 Dec 9].CrossRef

314.

De Lange J, Ly LV, Lodder K, Verlaan-De Vries M, Teunisse AFAS, Jager MJ, et al. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. Oncogene. 2012;31:1105–16 Available from: https://pubmed.ncbi.nlm.nih.gov/21765463/. [cited 2020 Dec 9].PubMedCrossRef

315.

Yang H, Jager MJ, Grossniklaus HE. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Investig Ophthalmol Vis Sci. 2010;51:2835–42 Available from: https://pubmed.ncbi.nlm.nih.gov/20089875/. [cited 2020 Dec 9].CrossRef

316.

Sudaka A, Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, et al. Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study. Invest New Drugs. 2013;31:59–65 Available from: https://pubmed.ncbi.nlm.nih.gov/22714791/. [cited 2020 Dec 14].PubMedCrossRef

317.

el Filali M, Ly LV, Luyten GPM, Versluis M, Grossniklaus HE, van der Velden PA, et al. Bevacizumab and intraocular tumors: an intriguing paradox. Mol Vis. 2012;18:2454–67 Available from: https://pubmed.ncbi.nlm.nih.gov/23077404/. [cited 2020 Dec 28].PubMedPubMedCentral

318.

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220–31 Available from: https://pubmed.ncbi.nlm.nih.gov/19249680/. [cited 2020 Dec 9].PubMedPubMedCentralCrossRef

319.

Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17(3):471-94. Available from: https://pubmed.ncbi.nlm.nih.gov/24482243/.

320.

Thompson EM, Neuwelt EA, Frenkel EP. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology. 2011;76:87–93 Available from: https://pubmed.ncbi.nlm.nih.gov/21205697/. Lippincott Williams and Wilkins; [cited 2020 Dec 9].PubMedPubMedCentralCrossRef

321.

Tura A, Pawlik VE, Rudolf M, Ernesti JS, Stutzer JN, Grisanti S, et al. Uptake of ranibizumab but not bevacizumab into uveal melanoma cells correlates with a sustained decline in VEGF-A levels and metastatic activities. Cancers (Basel). 2019;11(6):868. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628228/. MDPI AG; [cited 2020 Dec 20].

322.

Triozzi PL, Aldrich W, Dombos C. Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. Melanoma Res. 2008;18:420–30 Available from: https://pubmed.ncbi.nlm.nih.gov/18971787/. [cited 2020 Dec 20].PubMedCrossRef

323.

Lefevre G, Glotin AL, Calipel A, Mouriaux F, Tran T, Kherrouche Z, et al. Roles of stem cell factor/c-Kit and effects of Glivec®/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem. 2004;279:31769–79 Available from: https://pubmed.ncbi.nlm.nih.gov/15145934/. [cited 2020 Dec 20].PubMedCrossRef

324.

Fernandes BF, Di Cesare S, Belfort RN, Maloney S, Martins C, Castiglione E, et al. Imatinib mesylate alters the expression of genes related to disease progression in an animal model of uveal melanoma. Anal Cell Pathol. 2011;34:123–30 Available from: https://pubmed.ncbi.nlm.nih.gov/21606571/. [cited 2020 Dec 20].CrossRef

325.

Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, et al. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med. 2007;5 Available from: https://pubmed.ncbi.nlm.nih.gov/17640369/. [cited 2020 Dec 6].

326.

Jin Y, Zhang P, Wang Y, Jin B, Zhou J, Zhang J, et al. Neddylation blockade diminishes hepatic metastasis by dampening cancer stem-like cells and angiogenesis in uveal melanoma. Clin Cancer Res. 2018;24:3741–54 Available from: https://pubmed.ncbi.nlm.nih.gov/29233905/. American Association for Cancer Research Inc.[cited 2020 Dec 14].PubMedCrossRef

327.

Némati F, De Montrion C, Lang G, Kraus-Berthier L, Carita G, Sastre-Garau X, et al. Targeting Bcl-2/Bcl-X L induces antitumor activity in uveal melanoma patient-derived xenografts. PLoS One. 2014;9 Available from: https://pubmed.ncbi.nlm.nih.gov/24454684/. Public Library of Science; [cited 2020 Dec 14].

328.

Notting IC, Missotten GSOA, Sijmons B, Boonman ZFHM, Keunen JEE, Van Der Pluijm G. Angiogenic profile of uveal melanoma. Curr Eye Res. 2006;31:775–85 Available from: https://pubmed.ncbi.nlm.nih.gov/16966150/. [cited 2020 Dec 14].PubMedCrossRef

329.

Wang B, Li H, Yan H, Xiao JG. Genistein inhibited hypoxia-inducible factor-1α expression induced by hypoxia and cobalt chloride in human retinal pigment epithelium cells. Methods Find Exp Clin Pharmacol. 2005;27:179–84 Available from: https://pubmed.ncbi.nlm.nih.gov/15834450/. [cited 2020 Dec 14].PubMedCrossRef

330.

Wang B, Zou Y, Li H, Yan H, Pan JS, Yuan ZL. Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1α in a mouse model of oxygen-induced retinopathy. J Ocul Pharmacol Ther. 2005;21:107–13 Available from: https://pubmed.ncbi.nlm.nih.gov/15857276/. [cited 2020 Dec 14].PubMedCrossRef

331.

Wang B, Zou Y, Yuan ZL, Xiao JG. Genistein suppressed upregulation of vascular endothelial growth factor expression by cobalt chloride and hypoxia in rabbit retinal pigment epithelium cells. J Ocul Pharmacol Ther. 2003;19:457–64 Available from: https://pubmed.ncbi.nlm.nih.gov/14583137/. Mary Ann Liebert Inc.;[cited 2020 Dec 14].PubMedCrossRef

332.

Pan JS, Zhu HJ, Zhang B, Li H, Yan H, Wang B. Inhibitive effect of genistein on hypoxia-induced basic fibroblast growth factor expression in human retinal pigment epithelium cells. J Ocul Pharmacol Ther. 2006;22:103–9 Available from: https://pubmed.ncbi.nlm.nih.gov/16722796/. [cited 2020 Dec 14].PubMedCrossRef

333.

Alarcon GS. Tetracyclines for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2000;9(7):1491-8. Ashley Publications Ltd.

334.

Rudek MA, New P, Mikkelsen T, Phuphanich S, Alavi JB, Nabors LB, et al. Phase i and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. J Neurooncol. 2011;105:375–81 Available from: https://pubmed.ncbi.nlm.nih.gov/21547395/. [cited 2020 Dec 14].PubMedPubMedCentralCrossRef

335.

Chen LX, He YJ, Zhao SZ, Wu JG, Wang JT, Zhu LM, et al. Inhibition of tumor growth and vasculogenic mimicry by cucumin through downregulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol Ther. 2011;11:229–35 Available from: https://pubmed.ncbi.nlm.nih.gov/21084858/. [cited 2020 Dec 14].PubMedCrossRef

336.

Guenterberg KD, Grignol VP, Relekar KV, Varker KA, Chen HX, Kendra KL, et al. A pilot study of bevacizumab and interferon-α2b in ocular melanoma. Am J Clin Oncol Cancer Clin Trials. 2011;34:87–91 Available from: https://pubmed.ncbi.nlm.nih.gov/20458209/. [cited 2020 Dec 5].

337.

Solti M, Berd D, Mastrangelo MJ, Sato T. A pilot study of low-dose thalidomide and interferon α-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res. 2007;17:225–31 Available from: https://pubmed.ncbi.nlm.nih.gov/17625452/. [cited 2020 Dec 5].PubMedCrossRef

338.

Hofmann UB, Kauczok-Vetter CS, Houben R, Becker JC. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res. 2009;15:324–9 Available from: https://pubmed.ncbi.nlm.nih.gov/19118061/. [cited 2020 Dec 5].PubMedCrossRef

339.

Zeldis JB, Heller C, Seidel G, Yuldasheva N, Stirling D, Shutack Y, et al. A randomized phase II trial comparing two doses of lenalidomide for the treatment of stage IV ocular melanoma. J Clin Oncol. 2009;27:e20012 American Society of Clinical Oncology (ASCO).CrossRef

340.

Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, et al. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One. 2012;7(11):e48787. Available from: https://pubmed.ncbi.nlm.nih.gov/23226204/. [cited 2020 Dec 5].

341.

Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T. A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res. 2012;22:440–6 Available from: https://pubmed.ncbi.nlm.nih.gov/23114504/. [cited 2020 Dec 5].PubMedCrossRef

342.

Piperno-Neumann S, Servois V, Bidard F-C, Mariani P, Plancher C, Diallo A, et al. BEVATEM: Phase II study of bevacizumab (B) in combination with temozolomide (T) in patients (pts) with first-line metastatic uveal melanoma (MUM): final results. J Clin Oncol. 2013;31:9057 American Society of Clinical Oncology (ASCO).CrossRef

343.

Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, et al. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017;116:432–40 Available from: https://pubmed.ncbi.nlm.nih.gov/28103611/. Nature Publishing Group; [cited 2020 Dec 5].PubMedPubMedCentralCrossRef

344.

Scheulen ME, Kaempgen E, Keilholz U, Heinzerling L, Ochsenreither S, Abendroth A, et al. STREAM: A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (S) treatment of chemonaïve patients (pts) with metastatic uveal melanoma (MUM). J Clin Oncol. 2017;35:9511 American Society of Clinical Oncology (ASCO).CrossRef

345.

Piperno-Neumann S, Diallo A, Etienne-Grimaldi M, Bidard F, Rodrigues M, Plancher C, et al. Phase II Trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanoma. Oncologist. 2016;21:281 Available from: https://pubmed.ncbi.nlm.nih.gov/26911405/. Wiley;[cited 2020 Dec 20].PubMedPubMedCentralCrossRef

346.

Mouriaux F, Servois V, Parienti JJ, Lesimple T, Thyss A, Dutriaux C, et al. Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study. Br J Cancer. 2016;115:20–4 Available from: https://pubmed.ncbi.nlm.nih.gov/27253171/. Nature Publishing Group; [cited 2020 Dec 20].PubMedPubMedCentralCrossRef

347.

Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, et al. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017;116:432–40 Available from: https://pubmed.ncbi.nlm.nih.gov/28103611/. Nature Publishing Group; [cited 2020 Sep 11].PubMedPubMedCentralCrossRef

348.

Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, et al. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One. 2012;7(11):e48787. https://doi.org/10.1371/journal.pone.0048787.

349.

Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, et al. Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201). Clin Cancer Res. 2020;26:804–11 Available from: https://pubmed.ncbi.nlm.nih.gov/31558480/. American Association for Cancer Research Inc.;[cited 2020 Dec 21].PubMedCrossRef

350.

Search of: NCT01551459 - List results - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT01551459&cntry=&state=&city=&dist=. [cited 2020 Dec 9].

351.

Search of: NCT02068586 - List results - ClinicalTrials.gov.. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT02068586&cntry=&state=&city=&dist=. [cited 2020 Dec 9].

352.

Search of: NCT00489944 - List results - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT00489944&cntry=&state=&city=&dist=. [cited 2020 Dec 9].

353.

Search of: NCT01005472 - List results - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT01005472&cntry=&state=&city=&dist=. [cited 2020 Dec 9]

354.

Search of: NCT02158520 - List results - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT02158520&cntry=&state=&city=&dist=&Search=Search. [cited 2020 Dec 9]

355.

Search of: NCT00003339 - List results - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT00003339&cntry=&state=&city=&dist=. [cited 2020 Dec 9].

356.

Vaccine therapy and interleukin-12 with either alum or sargramostim after surgery in treating patients with melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00031733?term=NCT00031733&draw=2&rank=1. [cited 2020 Dec 9].

357.

Search of: NCT00811200 - List results - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT00811200&cntry=&state=&city=&dist=. [cited 2020 Dec 9].

358.

Stereotactic body radiation therapy and aflibercept in treating patients with uveal melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03712904?term=NCT03712904&draw=2&rank=1. [cited 2020 Dec 30].

359.

Prevention of neovascular glaucoma by intravitreal injections of anti-VEGF in patients treated with proton therapy for a large choroidal melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03172299?term=NCT03172299&draw=2&rank=1. [cited 2020 Dec 30].

360.

Lerner B, Stewart L, Horowitz D, Carvajal R. Mucosal melanoma: new insights and therapeutic options for a unique and aggressive disease. 2017 ; Available from: https://www.cancernetwork.com/review-article/mucosal-melanoma-new-insights-and-therapeutic-options-unique-and-aggressive-disease/page/0/1. [cited 2020 Dec 26]

361.

Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. JNCCN J Natl Compr Cancer Netw. 2012:345–56 Available from: https://pubmed.ncbi.nlm.nih.gov/22393195/. Harborside Press; [cited 2020 Dec 26].

362.

Spencer KR, Mehnert JM. Mucosal melanoma: Epidemiology, biology and treatment. Cancer Treat Res. 2016:295–320 Available from: https://pubmed.ncbi.nlm.nih.gov/26601869/. Kluwer Academic Publishers; [cited 2020 Dec 26].

363.

Ascierto PA, Accorona R, Botti G, Farina D, Fossati P, Gatta G, et al. Mucosal melanoma of the head and neck. Crit Rev Oncol Hematol. 2017:136–52 Available from: https://pubmed.ncbi.nlm.nih.gov/28325255/. Elsevier Ireland Ltd; [cited 2020 Dec 26].

364.

Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 2017:2104–17 Available from: https://pubmed.ncbi.nlm.nih.gov/28543693/. Wiley;[cited 2020 Dec 14].

365.

Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol. 2020:139–48 Available from: https://pubmed.ncbi.nlm.nih.gov/31655118/. Academic Press; [cited 2020 Dec 26].

366.

Gkiala A, Palioura S. Conjunctival melanoma: update on genetics, epigenetics and targeted molecular and immune-based therapies. Clin Ophthalmol. 2020:3137–52 Available from: https://pubmed.ncbi.nlm.nih.gov/33116365/. Dove Medical Press Ltd; [cited 2020 Dec 26].

367.

Yde SS, Sjoegren P, Heje M, Stolle LB. Mucosal melanoma: a literature review. Curr Oncol Rep. 2018; Available from: https://pubmed.ncbi.nlm.nih.gov/29569184/. Current Medicine Group LLC 1. [cited 2020 Dec 26].

368.

Rivera RS, Nagatsuka H, Siar CH, Gunduz M, Tsujigiwa H, Han PP, et al. Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma. Oncol Rep. 2008;19:657–61 Available from: https://pubmed.ncbi.nlm.nih.gov/18288398/. Spandidos Publications; [cited 2020 Dec 26].PubMed

369.

Song H, Jing G, Wang L, Guo W, Ren G. Periodic acid-Schiff-positive loops and networks as a prognostic factor in oral mucosal melanoma. Melanoma Res. 2016;26:145–52 Available from: https://pubmed.ncbi.nlm.nih.gov/26636907/. Lippincott Williams and Wilkins; [cited 2020 Dec 26].PubMedCrossRef

370.

Torabi SJ, Benchetrit L, Spock T, Cheraghlou S, Judson BL. Clinically node-negative head and neck mucosal melanoma: an analysis of current treatment guidelines & outcomes. Oral Oncol. 2019;92:67–76 Available from: https://pubmed.ncbi.nlm.nih.gov/31010627/. Elsevier Ltd; [cited 2020 Dec 26].PubMedCrossRef

371.

Buchbinder EI, Sosman JA, Lawrence DP, McDermott DF, Ramaiya NH, Van Den Abbeele AD, et al. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015;121:4007–15 Available from: https://pubmed.ncbi.nlm.nih.gov/26264378/. John Wiley and Sons Inc.; [cited 2020 Dec 23].PubMedCrossRef

372.

Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, et al. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer. 2017;123:2688–97 Available from: https://pubmed.ncbi.nlm.nih.gov/28334439/. Wiley; [cited 2020 Dec 23].PubMedCrossRef

373.

Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31:3182–90 Available from: https://pubmed.ncbi.nlm.nih.gov/23775962/. [cited 2020 Dec 23].PubMedPubMedCentralCrossRef

374.

Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, et al. Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition. Clin Cancer Res. 2015;21:2289–96 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013827/. American Association for Cancer Research Inc.; [cited 2020 Dec 23].

375.

Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019;119:168–78 Available from: https://pubmed.ncbi.nlm.nih.gov/31445199/. Elsevier Ltd; [cited 2020 Dec 23].PubMedCrossRef

376.

Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018;119:670–4 Available from: https://pubmed.ncbi.nlm.nih.gov/30202085/. Nature Publishing Group; [cited 2020 Dec 23].PubMedPubMedCentralCrossRef

377.

Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. Eur J Cancer. 2020;126:33–44 Available from: https://pubmed.ncbi.nlm.nih.gov/31901705/. Elsevier Ltd; [cited 2020 Aug 22].PubMedCrossRef

378.

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23 Massachussetts Medical Society.PubMedPubMedCentralCrossRef

379.

Maintenance treatment of toripalimab (JS001) in patients with unresectable locally advanced or metastatic mucosal melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04472806?term=NCT04472806&draw=2&rank=1. [cited 2020 Dec 30]

380.

Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04091217?term=NCT04091217&draw=2&rank=1. [cited 2020 Dec 30]

381.

Mason JO, Albert MA, Persaud TO, Vail RS. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina. 2007;27:903–7 Available from: http://journals.lww.com/00006982-200709000-00015. [cited 2020 Dec 9].PubMedCrossRef

382.

Ziemssen F, Voelker M, Altpeter E, Bartz-Schmidt KU, Gelisken F. Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma. Acta Ophthalmol Scand. 2007;85:579–80 Available from: https://pubmed.ncbi.nlm.nih.gov/17324216/. Wiley; [cited 2020 Dec 9].PubMedCrossRef

383.

Shields CL, Dalvin LA, Chang M, Mazloumi M, Fortin P, McGarrey M, et al. Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 Years) for uveal melanoma: comparison with nonrandomized historical control individuals. JAMA Ophthalmol. 2020;138:136–46 Available from: https://pubmed.ncbi.nlm.nih.gov/31830238/. American Medical Association; [cited 2020 Dec 14].PubMedCrossRef

384.

Yang X, Dalvin LA, Mazloumi M, Chang M, Shields JA, Mashayekhi A, et al. Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients. Clin Exp Ophthalmol. 2020;48:610–23 Available from: https://pubmed.ncbi.nlm.nih.gov/32277560/. Blackwell Publishing; [cited 2020 Dec 14].PubMedCrossRef

385.

Murray TG, Latiff A, Villegas VM, Gold AS. Aflibercept for radiation maculopathy study: a prospective, randomized clinical study. Ophthalmol Retin. 2019;3:561–6 Available from: https://pubmed.ncbi.nlm.nih.gov/31277797/. Elsevier Inc; [cited 2020 Dec 21].CrossRef

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hypoxia-dependent drivers of melanoma progression

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer

Exosomal ANGPTL1 attenuates colorectal cancer liver metastasis by regulating Kupffer cell secretion pattern and impeding MMP9 induced vascular leakiness

Correction to: RETRACTED ARTICLE: Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2

Correction to: Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner

Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling

Retraction Note: Dual loading miR-218 mimics and Temozolomide using AuCOOH@FA-CS drug delivery system: promising targeted antitumor drug delivery system with sequential release functions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer